NewsResearch
GOG-218: What the Ovarian cancer Trial Found
GOG-218 tested bevacizumab added to chemotherapy in ovarian cancer, measuring progression-free survival. Plain-language summary of a positive result on its main measure — and what it doesn't mean.
Original commentary from the Cancer Explained editorial team.
Historical context: this page explains an event dated 2011. It was published as an explainer on July 12, 2026 and is not breaking news.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
In brief
GOG-218 was phase 3, randomized, double-blind in ovarian cancer that compared bevacizumab added to chemotherapy and measured progression-free survival. It reported a positive result on its main measure.
Trial at a glance
| Field | Detail |
|---|---|
| Trial | GOG-218 |
| Identifier | Not recorded here |
| Phase | Phase 3 |
| Design | phase 3, randomized, double-blind |
| Cancer type | Ovarian cancer |
| Comparator | bevacizumab added to chemotherapy |
| Primary endpoint | progression-free survival |
| Reported result | A positive result on its main measure |
Who took part
The trial enrolled the population described in its report for ovarian cancer.
The main result
The trial's main finding concerned progression-free survival: GOG-218 reported a positive result on its main measure. Full numbers, follow-up, and statistical detail are held for verification against the peer-reviewed report or trial registry.
What the result means
Results like this help shape research and, sometimes, care — but a trial's finding is one piece of evidence, tied to the specific people and design it used.
What this story cannot tell you
- A positive trial does not automatically mean a treatment is approved or available; approval and access are separate steps.
- A response or progression-free-survival result is not the same as living longer; overall-survival data may take longer to mature.
- Trial participants are selected by specific criteria, so results may not apply to everyone with this cancer.
Questions worth asking
- Does this apply to my specific cancer type and situation?
- Is this treatment approved and available, or still investigational?
- What are the main side effects, and how would they be managed?
Sources
This article was written from the sources below, which were checked on the source-check date shown above.
How this article was prepared
Prepared by Cancer Explained's AI-assisted editorial system and checked against the sources listed below. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown.
Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.
Found an error, a broken source link, outdated information, or wording that feels insensitive? Report it here — we log and act on material corrections.